Diabetes, hypoglycemic drugs and pancreatic cancer

doi:10.3760/cma.j.issn.1673-422X.2018.03.013

Abstract

Abstract: About 80% of the patients with pancreatic cancer have glucose metabolism alterations, which suggests an association between diabetes and the occurrence and development of pancreatic cancer. Studies have shown that diabetes and hypoglycemic agents are closely related to the occurrence risk, clinical manifestation and prognosis of pancreatic cancer. Recent findings demonstrate that insulin resistance, hyperinsulinemia, the expression level of insulinlike growth factor related protein and inflammatory reaction are the possible mechanisms of the interaction between diabetes and pancreatic cancer. However, the definite mechanism still remains unclear, and further researches are still needed.

Key words: Pancreatic neoplasms, Diabetes mellitus, Hypoglycins, Molecular mechanisms of pharmacological action

Liang Biyu, He Weiming, He Xiaoyi, Ding Yuanlin, Yu Haibing. Diabetes, hypoglycemic drugs and pancreatic cancer[J]. Journal of International Oncology, 2018, 45(3): 183-186.

References

［1］ Shen H, Zhan M, Wang W, et al. Impact of diabetes mellitus on the survival of pancreatic cancer: a metaanalysis［J］. Onco Targets Ther, 2016, 9: 1679-1688. DOI: 10.2147/OTT.S95744. ［2］ Lee SH, Yoon SH, Lee HS, et al. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with preexisting diabetes mellitus type 2［J］. Dig Liver Dis, 2016, 48(4): 435-440. DOI: 10.1016/j.dld.2015.12.006. ［3］ Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults［J］. JAMA, 2013, 310(9): 948-959. DOI: 10.1001/jama.2013.168118. ［4］ Pang Y, Kartsonaki C, Guo Y, et al. Diabetes, plasma glucose and incidence of pancreatic cancer: a prospective study of 0.5 million Chinese adults and a metaanalysis of 22 cohort studies［J］. Int J Cancer, 2017, 140(8): 17811788. DOI: 10.1002/ijc.30599. ［5］ Er KC, Hsu CY, Lee YK, et al. Effect of glycemic control on the risk of pancreatic cancer: a nationwide cohort study［J］. Medicine (Baltimore), 2016, 95(24): e3921. DOI: 10.1097/MD.0000000000003921. ［6］ Lu Y, García Rodríguez LA, Malgerud L, et al. Newonset type 2 diabetes, elevated HbA1c, antidiabetic medications, and risk of pancreatic cancer［J］. Br J Cancer, 2015, 113(11): 16071614. DOI: 10.1038/bjc.2015.353. ［7］王慧慧, 王霄英. 胰腺癌患者的糖尿病患病率及影像表现［J］. 放射学实践, 2016, 31(2): 126-128. DOI: 10.13609/j.cnki.1000-0313.2016.02.007. ［8］王飞, 李校天. 胰腺癌与新发2型糖尿病的关系［J］. 承德医学院学报, 2016, 33(3): 203-204. DOI: 10.15921/j.cnki.cyxb.2016.03.010. ［9］周美岑, 马明磊, 李玉秀. 新发糖尿病——胰腺癌早期筛查和诊断的临床线索［J］. 中华老年多器官疾病杂志, 2016, 15(6): 418-421. DOI: 10.11915/j.issn.1671-5403.2016.06.098. ［10］ Eibl G, CruzMonserrate Z, Korc M, et al. Diabetes mellitus and obesity as risk factors for pancreatic cancer［J］. J Acad Nutr Diet, 2018， 118(4): 555-567. DOI: 10.1016/j.jand.2017.07.005. ［11］ CarrerasTorres R, Johansson M, Gaborieau V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a mendelian randomization study［J］. J Natl Cancer Inst, 2017, 109(9): 495. DOI: 10.1093/jnci/djx012. ［12］ Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology［J］. Nat Rev Cancer, 2015, 15(8): 484-498. DOI: 10.1038/nrc3967. ［13］ Toriola AT, StolzenbergSolomon R, Dalidowitz L, et al. Diabetes and pancreatic cancer survival: a prospective cohortbased study［J］. Br J Cancer, 2014, 111(1): 181-185. DOI: 10.1038/bjc.2014.224. ［14］ Hwang A, Narayan V, Yang YX. Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study［J］. Cancer, 2013, 119(2): 404-410. DOI: 10.1002/cncr.27731. ［15］ Hart PA, Law RJ, Frank RD, et al. Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study［J］. Am J Gastroenterol, 2014, 109(9): 1484-1492. DOI: 10.1038/ajg.2014.193. ［16］ Beg MS, Dwivedi AK, Ahmad SA, et al. Impact of diabetes mellitus on the outcome of pancreatic cancer［J］. PLoS One, 2014, 9(5): e98511. DOI: 10.1371/journal.pone.0098511. ［17］郭延勋, 马士崟. 二甲双胍的抗肿瘤作用［J］. 国际肿瘤学杂志, 2015, 42(4): 281-283. DOI: 10.3760/cma.j.issn.1673-422X.2015.04.001. ［18］ Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intentiontotreat trial［J］. Diabetes Care, 2014, 37(9): 2522-2532. DOI: 10.2337/dc140584. ［19］赵太云, 王胤, 程大伟, 等. 噻唑烷二酮类对2型糖尿病并发癌症风险的荟萃分析［J］. 中华消化病与影像杂志(电子版), 2015, 5(6): 25-32. DOI: 10.3877/cma.j.issn.2095-2015.2015.06.008. ［20］ Zhang JW, Sun Q. Metformin may improve the prognosis of patients with pancreatic cancer［J］. Asian Pac J Cancer Prev, 2015, 16(9): 3937-3940. ［21］ Choi Y, Kim TY, Oh DY, et al. The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy［J］. Cancer Res Treat, 2016, 48(1): 171-179. DOI: 10.4143/crt.2014.292. ［22］ Jang WI, Kim MS, Kang SH, et al. Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide populationbased study in korea［J］. Oncotarget, 2017, 8(6): 95879596. DOI: 10.18632/oncotarget.14525. ［23］ Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a doubleblind, randomised, placebocontrolled phase 2 trial［J］. Lancet Oncol, 2015, 16(7): 839-847. DOI: 10.1016/S1470-2045(15)00027-3. ［24］ Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an openlabel, randomized phase Ⅱ trial［J］. Clin Cancer Res, 2016, 22(5): 1076-1085. DOI: 10.1158/1078-0432.CCR-15-1722. ［25］ Chaiteerakij R, Petersen GM, Bamlet WR, et al. Metformin use and survival of patients with pancreatic cancer: a cautionary lesson［J］. J Clin Oncol, 2016, 34(16): 1898-1904. DOI: 10.1200/JCO.2015.63.3511. ［26］ Yang YX, Rustgi AK. Impact of metformin on advanced pancreatic cancer survival: too little, too late?［J］. Clin Cancer Res, 2016, 22(5): 10311033. DOI: 10.1158/1078-0432.CCR-15-2494. ［27］ Biadgo B, Abebe M. Type 2 diabetes mellitus and its association with the risk of pancreatic carcinogenesis: a review［J］. Korean J Gastroenterol, 2016, 67(4): 168-177. DOI: 10.4166/kjg.2016.67.4.168. ［28］张晓辉, 王锦波. 糖尿病致胰腺癌的机制研究现状［J］. 中华灾害救援医学, 2016, 4(5): 281-284. DOI: 10.13919/j.issn.20956274.2016.05.013.

[1]	Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients [J]. Journal of International Oncology, 2023, 50(10): 608-613.
[2]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili. Research progress of avermectins in anti-tumor [J]. Journal of International Oncology, 2022, 49(6): 353-356.
[3]	Yan Zhiying, Mao Yifeng, Zhu Yingwei, Xu Kequn. Role of heterogeneity of cancer-associated fibroblasts in targeted therapy of pancreatic cancer [J]. Journal of International Oncology, 2021, 48(5): 308-312.
[4]	Zhong Yang, He Miao, Liu Zhi, Chen Jianyu, Zhang Guangnian, Qin Long, Li Ting, Li Jianshui. Effects of Ophiopogon D combined with cyclooxygenase-2 silencing on proliferation, migration and invasion of human pancreatic cancer BxPC-3 cells [J]. Journal of International Oncology, 2021, 48(10): 583-590.
[5]	Li Keke, Kong Panpan, Yi Chao, Wang Xiyan, Yan Dong. Expression of lymphoid enhancer factor-1 in pancreatic ductal adenocarcinoma and its effect on prognosis [J]. Journal of International Oncology, 2021, 48(10): 608-613.
[6]	Chen Xiaoxu, Yu Yang, Zhang Tianxue. A prognostic risk assessment model for pancreatic cancer established based on immune-related lncRNAs [J]. Journal of International Oncology, 2020, 47(8): 472-479.
[7]	Wang Xue, Ji Guoxin, Ji Chao, Yang Xingsheng. Effects of metformin on prognosis of type Ⅰ endometrial carcinoma patients complicated with type 2 diabetes mellitus [J]. Journal of International Oncology, 2020, 47(7): 404-408.
[8]	Zhao Xiaoling, Kong Weimin. Current status of basic and clinical research on metformin in endometrial cancer [J]. Journal of International Oncology, 2020, 47(7): 440-443.
[9]	Tian Chunfang, Sha Dan. Zinc finger proteins and digestive system cancers [J]. Journal of International Oncology, 2020, 47(2): 115-118.
[10]	Ji Zhouxin, He De. Microbiota and pancreatic cancer [J]. Journal of International Oncology, 2020, 47(1): 46-50.
[11]	Li Qinghe, Liu Huichun, Zhang Jiayao, Li Wei. Study on the molecular mechanism of miR-200b-3p regulates the proliferation, invasion, migration and apoptosis of pancreatic cancer cells by down-regulating VEGFA [J]. Journal of International Oncology, 2019, 46(11): 649-656.
[12]	Li Zhi, Xu Jingkai, Zhang Bo. Mechanisms of long non-coding RNAs in tumors [J]. Journal of International Oncology, 2018, 45(4): 220-222.
[13]	Li Zhijian, He De. Research progress on liquid biopsy in pancreatic cancer [J]. Journal of International Oncology, 2018, 45(3): 180-182.
[14]	Chen Luojun, Li Na, Tian Jingyuan, Xu Bin, Song Qibin. Analysis of prognosis factors in nonfunctional pancreatic neuroendocrine carcinoma [J]. Journal of International Oncology, 2018, 45(12): 721-726.
[15]	QIU Mei-Qing, WANG Tao, TONG Zhong-Sheng, JIA Yong-Sheng. Effects and mechanism of overexpression of Mfn2 gene on photodynamic therapy sensitivity of T47D cells in human breast cancer [J]. Journal of International Oncology, 2017, 44(8): 641-646.